Novo Nordisk’s High-Dose Wegovy Yields 28% Weight Loss, Hims & Hers Partnership
Novo Nordisk released trial data showing patients on its higher-dose Wegovy achieved up to 28% weight loss, 84% of which was from fat, while preserving muscle health. The company also partnered with Hims & Hers to broaden access to FDA-approved GLP-1 therapies including injectable and oral Wegovy options.
1. High-Dose Wegovy Trial Results
Novo Nordisk released data from a late-stage trial showing that patients treated with its higher-dose Wegovy achieved an average weight reduction of 28%, with 84% of the loss attributed to body fat. The study also highlighted preservation of muscle function and measurable improvements in muscle health over the treatment period.
2. Hims & Hers Partnership and Access Expansion
The company has entered a strategic collaboration with Hims & Hers Health to expand distribution of its FDA-approved GLP-1 medications, offering both injectable and oral Wegovy formulations alongside Ozempic pens. Eligible customers can access these therapies through the consumer platform, where pricing on Wegovy starts at $149 per month to drive broader patient reach.